ShareThis Page
Canadian company ordered to forfeit millions in drug mislabeling scheme |

Canadian company ordered to forfeit millions in drug mislabeling scheme

Patrick Sison/AP
Abuse of painkillers, heroin, fentanyl and other opioids across the country has resulted in tens of thousands of children being taken from their homes and placed in the foster care system.

A British Columbia, Canada, company was fined $150,000 and ordered to forfeit millions of dollars, and three Canadian men were fined and sentenced to probation for misbranding prescription drugs and money laundering conspiracy, U.S. Attorney Scott W. Brady said Tuesday.

U.S. District Judge Cathy Bissoon ordered Quantum Solutions, SRL, to pay a $150,000 fine and forfeit $4,235,000, prosecutors said.

British Columba residents Tony Lee, 41, of Vancouver; Billy Lee, 43, of White Rock; and Tarnjeet Uppal, 37, of Surray were each sentenced to three years probation and a fine of $55,000.

Quantum, registered in Barbados, bought prescription drugs made for foreign markets and sold wholesale quantities to three pharmacists in Western Pennsylvania. The pharmacies were not identified.

None of the prescription drugs met FDA approval because they were made and labeled for use outside of the United States, Brady said.

Quantum purchased the drugs from suppliers in Turkey, Great Britain and other countries. The defendants arranged for these misbranded drugs to be sent to a re-shipper in the United Kingdom. The UK re-shipper was instructed to unpack the drugs, repack them in several small packages, put misleading labeling and shipping documentation on them and understate the dollar value of the contents to create the appearance to U.S. Customs and Border Protection that the drugs were health care products for the personal use of the addressee, prosecutors said.

The small packages were sent to Washington state and New York state re-shippers known to the U.S. Attorney, where they were once again unpacked and repacked for delivery in the United States. Wholesale quantities of these misbranded drugs intended for use in foreign markets were purchased by three pharmacists in Western Pennsylvania. The wire transfers, checks and credit card payments from the pharmacists traveled from Western Pennsylvania to Canada and Barbados.

None of the re-shippers were licensed in the United States.

“Distributing prescription drugs produced and labeled for use outside of the United States within our borders not only violates federal law but also threatens the health and safety of our citizens,” Brady said. “We are committed to investigating and prosecuting any drug company that illegally circumvents the regulated process for the distribution of prescription drugs.”

“Criminals who distribute misbranded prescription drugs from outside the U.S. supply chain put the health of all U.S. consumers at risk,” said Mark S. McCormack, special agent in charge of the FDA’s Criminal Investigations’ Metro Washington Field Office. “Our skilled cybercrime investigators will continue to disrupt and dismantle illegal prescription drug distribution networks.”

“The role of IRS-Criminal Investigation in a case like this is to follow the money, which in turn allows us to disrupt and dismantle the organization,” said Guy Ficco, special agent in charge of the IRS-Criminal Investigation. “The defendants who perpetrated this scheme put the American public at risk. By providing our financial expertise, IRS-CI is committed to working with our partners at the FDA and the U.S. Attorney’s Office to see to it that criminals like this are stopped.”

Chuck Biedka is a Tribune-Review staff writer. You can contact Chuck at 724-226-4711, [email protected] or via Twitter @ChuckBiedka.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.